New York State Teachers Retirement System Takes $376,000 Position in Amneal Pharmaceuticals, Inc. $AMRX

New York State Teachers Retirement System bought a new position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 30,243 shares of the company’s stock, valued at approximately $376,000.

A number of other large investors have also added to or reduced their stakes in AMRX. Spire Wealth Management increased its position in shares of Amneal Pharmaceuticals by 66.6% in the fourth quarter. Spire Wealth Management now owns 2,558 shares of the company’s stock valued at $32,000 after acquiring an additional 1,023 shares during the period. Intech Investment Management LLC boosted its holdings in shares of Amneal Pharmaceuticals by 1.2% during the fourth quarter. Intech Investment Management LLC now owns 97,573 shares of the company’s stock worth $1,229,000 after purchasing an additional 1,159 shares during the period. Hsbc Holdings PLC boosted its holdings in shares of Amneal Pharmaceuticals by 1.6% during the fourth quarter. Hsbc Holdings PLC now owns 101,945 shares of the company’s stock worth $1,297,000 after purchasing an additional 1,569 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Amneal Pharmaceuticals by 2.4% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 68,137 shares of the company’s stock worth $859,000 after purchasing an additional 1,582 shares during the last quarter. Finally, Comerica Bank grew its stake in shares of Amneal Pharmaceuticals by 56.1% in the fourth quarter. Comerica Bank now owns 4,690 shares of the company’s stock worth $59,000 after purchasing an additional 1,685 shares during the last quarter. Institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals Price Performance

AMRX stock opened at $16.69 on Wednesday. Amneal Pharmaceuticals, Inc. has a 1 year low of $7.66 and a 1 year high of $17.86. The company has a market cap of $5.32 billion, a P/E ratio of 43.92 and a beta of 1.26. The firm has a 50-day moving average of $14.80 and a 200 day moving average of $13.80.

Amneal Pharmaceuticals (NASDAQ:AMRX) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.27 EPS for the quarter. The business had revenue of $722.52 million during the quarter. Amneal Pharmaceuticals had a net margin of 4.01% and a negative return on equity of 313.96%. On average, equities research analysts expect that Amneal Pharmaceuticals, Inc. will post 0.92 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have commented on AMRX shares. Barclays upped their price target on Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a research report on Wednesday, May 20th. Wall Street Zen upgraded Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Sunday. UBS Group began coverage on Amneal Pharmaceuticals in a research note on Friday, April 17th. They set a “buy” rating and a $19.00 target price on the stock. Weiss Ratings downgraded Amneal Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, May 26th. Finally, Zacks Research lowered Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, April 6th. Five investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, Amneal Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $15.80.

Insider Activity at Amneal Pharmaceuticals

In other news, Director Deborah M. Autor sold 34,819 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $12.94, for a total value of $450,557.86. Following the completion of the transaction, the director owned 93,660 shares in the company, valued at $1,211,960.40. This trade represents a 27.10% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 17.30% of the stock is currently owned by insiders.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.